A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer. (September 2019)

• Record Type: Journal Article
• Authors: Guo, Jia; Wang, Xiaohong; Wang, Ying; Wang, Liying; Hua, Shucheng
• Is Part Of: Lung cancer. Volume 135(2019)
• Page Start: 47
• Page End: 55
• Publication Date: 2019-09
• Subjects: IRF5 interferon regulatory factor 5 -- NSCLC non-small cell lung cancer -- AD adenocarcinoma -- SQ squamous cell carcinoma -- CT cancer tissues -- PCT para-carcinoma tissues -- ES early stage -- PS progressive stage -- HC healthy controls -- AUC area under the receiver-operating characteristics curve -- CI confidence interval -- OR odds ratio -- WBCs white blood cells -- NE neutrophil -- MO monocyte -- LY lymphocyte -- qRT-PCR quantitative reverse transcription-polymerase chain reaction; A8700; Interferon regulatory factor 5 -- Non-small cell lung cancer -- Biomarker -- Early diagnosis; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2019.07.008
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: The IRF5 expression level is associated with NSCLC severity. Elevated IRF5 in WBCs correlate with IP-10 and IL-10 levels in NSCLC patient plasma. Upregulated IRF5 in WBCs can be a promising early warning biomarker assisting NSCLC diagnosis. Abstract: Objectives: Non-small cell lung cancer (NSCLC) accounts for 85%–90% of lung cancer cases and is a covert disease lacking early symptoms. Since cancer is recognised as an inflammation-associated condition, we analysed the relationship between the expression of interferon regulatory factor 5 (IRF5), a key transcription factor controlling inflammatory responses, and NSCLC development with the aim of identifying a warning biomarker for early diagnosis of the disease. Materials and methods: The expression of IRF5 and its associated inflammatory factors IL-6, IL-10, IP-10, and TNF-α in the peripheral blood of NSCLC patients (n = 66) and healthy controls (n = 42) was analysed by quantitative RT-PCR, flow cytometry, and a cytometric bead array. IRF5 protein expression in NSCLC tissues (n = 102) was detected by Western blotting. The diagnostic value of IRF5 expression was determined by a receiver-operating characteristic (ROC) curve analysis. Results: The protein levels of IRF5, IL-6, and IP-10 were significantly higher in the peripheral blood of NSCLC patients than in that of healthy controls. IP-10 levels in plasma and IL-10 mRNA expression in white blood cells (WBCs) were significantly upregulated in early-stage NSCLC, whereas plasma IL-6 and IL-10 were elevated in the progressive stage. IRF5 protein levels in WBCs were positively correlated with plasma IP-10 but negatively correlated with plasma IL-10. Furthermore, the mRNA and protein levels of IRF5 in WBCs were significantly elevated in patients with early stage NSCLC compared to those in the progressive stage. Additionally, IRF5 protein levels were significantly lower in NSCLC tumour tissues than those in normal lung tissues. Conclusions: IRF5 levels in WBCs can be significantly upregulated in early stage NSCLC and were shown to have diagnostic value as an early warning biomarker of NSCLC development.